Polypeptides useful for appetite suppression

• US 7,544,662 B2
• Filed: 08/05/2005
• Issued: 06/09/2009
• Est. Priority Date: 06/17/1993
• Status: Expired due to Fees

• Current Assignee: Carle Development Foundation
• Original Assignee: Carle Development Foundation
• Inventors: Shoemaker, James D., Nelson, Ralph A.
• Primary Examiner(s): Lankford; L Blaine
• Assistant Examiner(s): UNDERDAHL, THANE E
• Application Number:
  US11/198,768
• Publication Number:
  US 20060276401A1
• Time in Patent Office: 1,404 Days
• Field of Search: 514/12, 514/18, 514/19, 930/10
• US Class Current: 514/1.1
• CPC Class Codes: A61K 35/16 Blood plasma; Blood serum umbilical cord blood A61K35/51
• CPC Class Codes: A61K 35/22 Urine; Urinary tract, e.g. kidney or bladder; Intraglomerular mesangial cells; Renal mesenchymal cells; Adrenal gland
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: C07K 14/51 Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
• CPC Class Codes: C07K 7/08 having 12 to 20 amino acids gastrins C07K14/595; somatostatins C07K14/655; melanotropins C07K14/68

Abstract

The present invention relates to polypeptides obtained from bear derivative isolate which are useful in suppressing appetite. The polypeptides of the present invention are most preferably between 12 and 13 amino acid residues in length and a mass of about 1249. The present invention also relates to a method of treating obesity by administering to obese subjects an effective amount of the polypeptides of the present invention.

Claims

1. A method of treating obesity by administering to obese subjects a therapeutically effective amount of polypeptides having between about 12 and 13 amino acid residues in length and wherein the polypeptide comprises a compound selected from the group consisting of RTGEGFLVTGGGV (SEQ ID NO:

1) and VSKEGFLVTGGR (SEQ ID NO;

     2).

2. The method of claim 1 wherein the polypeptide comprises a compound comprising the following formula:

RTGEGFLVTGGGV (SEQ ID NO;

     1).

3. The method of claim 1 wherein the polypeptide comprises a compound comprising the following formula:

VSKEGFLVTGGR (SEQ ID NO;

     2).

4. The method of claim 1 wherein the polypeptide comprises a mixture of RTGEGFLVTGGGV (SEQ ID NO:

1) and VSKEGFLVTGGR (SEQ ID NO;

     2).

5. A composition for treating obesity comprising a therapeutically effective level of a polypeptide having between about 12 and 13 amino acid residues in length and wherein said polypeptide is selected from the group consisting of RTGEGFLVTGGGV (SEQ ID NO:

1) and VSKEGFLVTGGR (SEQ ID NO;

     2) and a pharmaceutically acceptable carrier.

6. The composition of claim 5 wherein the polypeptide comprises a compound comprising the following formula:

RTGEGFLVTGGGV (SEQ ID NO;

     1).

7. The composition of claim 5 wherein the polypeptide comprises a compound comprising the following formula:

VSKEGFLVTGGR (SEQ ID NO;

     2).

8. The composition of claim 5 wherein the polypeptide comprises a mixture of RTGEGFLVTGGGV (SEQ ID NO:

1) and VSKEGFLVTGGR (SEQ ID NO;

     2).